This CME-certified Expert Review, featuring an interactive video with clinical opinion poll questions and downloadable slides, focuses on the treatment of metastatic breast cancer, specifically beyond second-line treatment.
Robert Coleman, MD, FRCP, FRCPEMedical Director, prIME Oncology
University of Sheffield
Weston Park Hospital
Sheffield, United Kingdom
Joyce O’Shaughnessy, MDBaylor University Medical Center
Dallas, Texas, United States
Denise Yardley, MDSarah Cannon Research Institute
Nashville, Tennessee, United States
- Chemotherapy for advanced breast cancer, particularly beyond second-line, for patients with estrogen receptor–positive and triple-negative breast disease
- Goals of chemotherapy beyond second-line
- Selection of optimal therapy
- Balancing treatment efficacy and adverse event management
- Agents used beyond the second-line, including epothilones
- Ongoing trials
- Novel agents
After successful completion of this educational activity, participants should be able to:
- Incorporate therapies for advanced/metastatic breast cancer into individualized treatment plans for patients based upon an evaluation of efficacy and safety data, as well as patient and tumor characteristics
- Assess clinical trial data for the use of epothilones in (neo)adjuvant therapy and combinations with targeted treatment
- Identify common or significant adverse events associated with treatment of advanced/metastatic breast cancer beyond the second-line setting, and the effective strategies for their prevention and/or management
This educational activity is specifically designed for medical oncologists, fellows, nurses, physician assistants, nurse practitioners, and other healthcare providers who treat/manage patients with metastatic breast cancer.
This activity is provided by prIME Oncology.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
prIME Oncology designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This educational activity is supported by a grant from R-Pharm US.
March 2, 2016
October 31, 2017